Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 12 January 2018

IBA SA : TRANSPARENCY NOTIFICATION

IBA SA    

Published: 18:00 CET 12-01-2018 /GlobeNewswire /Source: IBA SA / : IBAB /ISIN: BE0003766806


IBA - TRANSPARENCY NOTIFICATION

 

Louvain-la-Neuve, Belgium, January 12, 2018, 17.35 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on January 12, 2018.

 

 

Reason for the notification

Upwards crossing of the 3% threshold further to the acquisition of shares -and thus voting rights- held as loan collateral

Persons subject to the notification requirement

IBA SA, issuer

Persons that dispose of voting rights

Kempen Capital Management NV

Transaction date

 

01/01/2018

Threshold that is crossed (in %)

 

3%

Upwards crossing further to the acquisition of voting rights

Denominator

 

29 962 246

Voting rights (number)

 

900 174

Voting rights (%)

 

3,00%

Chain of control

Van Lanschot Kempen N.V. < 100%> F. van Lanschot Banklers NV <100%> kempen & Co NV <100%> Kempen Capital Management NV. Kempen se réfère à la declaration d'indépendance (datée du 15 novembre 2017).

Additional information

Kempen Capital Management NV appeals for Art. 11 of the (Transparency) Law (May 2, 2007), by which an exemption is acquired.

 

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

 

 

 

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

 

 

For further information, please contact:

 

IBA

 

Stephanie Bauwin

Legal Counsel

+32 10 203 924

Stephanie.bauwin@iba-group.com

 



20180112 transparency Notification EN



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: IBA SA, Chemin du Cyclotron 3, Louvain-la-Neuve 1348, Belgium
If you would like to unsubscribe and stop receiving these e-mails click here.